Patent US5116964A successfully refreshed from Google Patents.
US5116964A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid immunoglobulins
Assignee: Genentech Inc
•
Filing: 1989-11-22
•
Granted: 1992-05-26
•
Expires: 2009-11-22
Abstract
Abstract Immunoglobulin fusion polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.
Inventors
- 👤 Daniel J. Capon
- 👤 Laurence A. Lasky
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 23:07
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; A; A61; A61P; A61P25/00; A61P25/28; A61P31/00; A61P31/12; A61P37/00; A61P37/02; A61P9/00; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/70503; C07K14/70514; C07K16/00; C07K16/18; C07K16/28; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/04; C07K2319/30; C07K2319/32; C07K2319/33; C07K2319/70; C07K2319/705
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
54 words
Nucleic acid encoding a polypeptide fusion comprising a ligand binding partner protein containing more than one polypeptide chain, wherein the ligand binding partner protein is not a platelet growth factor receptor or an insulin receptor, one of said chains being fused to an immunoglobulin constant region through C- or N-terminal amino or carboxyl groups.
Claim 2
Dependent Claim
54 words
Nucleic acid encoding a polypeptide fusion comprising a ligand binding partner protein containing more than one polypeptide chain, wherein the ligand binding partner protein is not a platelet growth factor receptor or an insulin receptor, one of said chains being fused to an immunoglobulin constant region through C- or N-terminal amino or carboxyl groups.
Claim 3
Dependent Claim
98 words
Nucleic acid encoding a polypeptide fusion of a ligand binding partner protein and an immunoglobulin chain, wherein the ligand binding partner protein is not a platelet growth factor receptor or an insulin receptor, said ligand binding partner protein and said immunoglobulin chain being fused through C- or N-terminal amino or carboxyl groups, and said fusion further comprising an additional fusion of an agent selected from the group consisting of a multiple subunit (chain) polypeptide, a portion of an immunoglobulin superfamily member, a toxin and a polypeptide therapeutic agent not otherwise associated with an immunoglobulin, and an immunoglobulin chain.
Claim 4
Dependent Claim
98 words
Nucleic acid encoding a polypeptide fusion of a ligand binding partner protein and an immunoglobulin chain, wherein the ligand binding partner protein is not a platelet growth factor receptor or an insulin receptor, said ligand binding partner protein and said immunoglobulin chain being fused through C- or N-terminal amino or carboxyl groups, and said fusion further comprising an additional fusion of an agent selected from the group consisting of a multiple subunit (chain) polypeptide, a portion of an immunoglobulin superfamily member, a toxin and a polypeptide therapeutic agent not otherwise associated with an immunoglobulin, and an immunoglobulin chain.
Claim 5
Dependent Claim
22 words
The nucleic acid of claim 2 wherein said ligand binding partner is LHR and said agent in said additional fusion is CD4.
Claim 6
Dependent Claim
39 words
Nucleic acid encoding a polypeptide fusion comprising a ligand binding partner protein which comprises a LHR and an immunoglobulin chain, in which the ligand binding partner protein and immunoglobulin are fused through C- or N-terminal amino or carboxyl groups.
Claim 7
Dependent Claim
39 words
Nucleic acid encoding a polypeptide fusion comprising a ligand binding partner protein which comprises a LHR and an immunoglobulin chain, in which the ligand binding partner protein and immunoglobulin are fused through C- or N-terminal amino or carboxyl groups.
Claim 8
Dependent Claim
21 words
The nucleic acid of claim 4 wherein said immunoglobulin chain is obtained from IgG1, IgG2, IgG3, IgG4, IgE, IgD or IgM.
Claim 9
Dependent Claim
19 words
The nucleic acid of claim 4 wherein in said LHR the transmembrane and the cytoplasmic domains have been deleted.
Claim 10
Dependent Claim
32 words
The nucleic acid of claim 6 wherein the transmembrane and cytoplasmic domain deleted LHR is fused at its C-terminus to the N-terminus of an human IgG immunoglobulin heavy chain constant region sequence.
Claim 11
Dependent Claim
55 words
The nucleic acid of claim 7 wherein the transmembrane and cytoplasmic domain deleted LHR is fused at its C-terminus to the N-terminus of an IgG immunoglobulin sequence beginning in the hinge region just upstream of the papain cleavage site at residue 216, taking the first residue of the heavy chain constant region to be 114.
References Cited (Backward Citations)
EP0125023A1
Cited
EP0173494A2
Cited
EP0207402A2
Cited
EP0271227A2
Cited
EP0288809A1
Cited
EP0294703A2
Cited
EP0308381A1
Cited
EP0308936A2
Cited
EP0314317A1
Cited
EP0322094A1
Cited
WO1989004872A1
Cited
EP0325262A2
Cited
EP0325224A2
Cited
EP0346316A2
Cited
WO1990002338A1
Cited
WO1990005144A1
Cited
EP0386906A1
Cited
EP0391088A2
Cited
EP0394827A1
Cited
EP0399666A1
Cited
WO1990014103A1
Cited
WO1991000360A1
Cited
EP0413622A1
Cited
EP0414178A2
Cited
WO1991004329A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-05-26 | 1995-11-25 | 1996-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-05-26 | 1999-11-25 | 2000-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-05-26 | 2003-11-25 | 2004-05-26 | $7700.00 | Window Closed / Lapsed |